For Biosimilars, A Mid-Review Cycle Product Quality Discussion Appears To Be A Bad Omen
Executive Summary
Only about one-third of biosimilars received a first-cycle approval from US FDA after product quality discussions during the mid-assessment-cycle meeting, according to an interim report on the biosimilar application review program.
You may also be interested in...
US FDA Biosimilar Review Information Requests Should Come Earlier, With Longer Response Times
An FDA consultant and industry representatives recommend streamlining information requests during 351(k) application reviews and giving companies more than two days to respond; Eastern Research Group’s final assessment of the BsUFA II program finds positive views, but industry says more transparency is needed on timelines for delayed inspections.
US FDA Biosimilar Review Information Requests Should Come Earlier, With Longer Response Times
An FDA consultant and industry representatives recommend streamlining information requests during 351(k) application reviews and giving companies more than two days to respond; Eastern Research Group’s final assessment of the BsUFA II program finds positive views, but industry says more transparency is needed on timelines for delayed inspections.
US Biosimilar Approvals In 2021 Were Few But Included Many Firsts
While US biosimilar approvals have been somewhat thin on the ground in 2021 – with the pandemic driving inspection-related delays for multiple products – there were nevertheless several firsts this year, including the first two interchangeables and the first ophthalmic biosimilar.